Krystal Biotech (NASDAQ:KRYS) Earns “Overweight” Rating from Cantor Fitzgerald

Krystal Biotech (NASDAQ:KRYS)‘s stock had its “overweight” rating restated by equities researchers at Cantor Fitzgerald in a research report issued on Thursday, Benzinga reports.

KRYS has been the subject of a number of other research reports. HC Wainwright raised their target price on Krystal Biotech from $200.00 to $221.00 and gave the stock a “buy” rating in a research note on Wednesday. Chardan Capital lifted their target price on Krystal Biotech from $153.00 to $208.00 and gave the stock a “buy” rating in a report on Monday, August 5th. Evercore ISI increased their price target on shares of Krystal Biotech from $201.00 to $206.00 and gave the stock an “outperform” rating in a report on Monday, August 12th. Finally, Citigroup reaffirmed a “neutral” rating and issued a $204.00 price objective (up from $195.00) on shares of Krystal Biotech in a report on Tuesday, August 6th. One analyst has rated the stock with a hold rating and nine have assigned a buy rating to the company’s stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $190.22.

Krystal Biotech Trading Down 0.2 %

Shares of Krystal Biotech stock traded down $0.32 during trading on Thursday, hitting $203.59. 32,147 shares of the stock traded hands, compared to its average volume of 360,518. The firm has a market cap of $5.81 billion, a P/E ratio of 108.87 and a beta of 0.84. Krystal Biotech has a 52-week low of $93.95 and a 52-week high of $219.34. The stock’s fifty day simple moving average is $193.15 and its 200 day simple moving average is $172.68.

Krystal Biotech (NASDAQ:KRYS) last announced its quarterly earnings results on Monday, August 5th. The company reported $0.53 EPS for the quarter, beating the consensus estimate of $0.50 by $0.03. The firm had revenue of $70.28 million for the quarter, compared to analysts’ expectations of $65.27 million. The business’s quarterly revenue was up 70283900.0% on a year-over-year basis. During the same quarter in the prior year, the business posted ($1.25) EPS. As a group, equities analysts expect that Krystal Biotech will post 2 EPS for the current year.

Insider Buying and Selling

In other Krystal Biotech news, insider Suma Krishnan sold 25,000 shares of the business’s stock in a transaction that occurred on Tuesday, June 11th. The stock was sold at an average price of $175.76, for a total transaction of $4,394,000.00. Following the completion of the sale, the insider now directly owns 1,525,882 shares in the company, valued at approximately $268,189,020.32. The transaction was disclosed in a document filed with the SEC, which is available through this link. 14.10% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Krystal Biotech

Large investors have recently bought and sold shares of the company. EFG Asset Management North America Corp. grew its position in shares of Krystal Biotech by 0.5% in the second quarter. EFG Asset Management North America Corp. now owns 12,555 shares of the company’s stock valued at $2,308,000 after purchasing an additional 60 shares in the last quarter. GAMMA Investing LLC grew its position in shares of Krystal Biotech by 160.3% in the second quarter. GAMMA Investing LLC now owns 151 shares of the company’s stock valued at $28,000 after purchasing an additional 93 shares in the last quarter. Nisa Investment Advisors LLC grew its position in shares of Krystal Biotech by 11.1% in the second quarter. Nisa Investment Advisors LLC now owns 940 shares of the company’s stock valued at $173,000 after purchasing an additional 94 shares in the last quarter. Arizona State Retirement System grew its position in shares of Krystal Biotech by 2.1% in the second quarter. Arizona State Retirement System now owns 5,147 shares of the company’s stock valued at $945,000 after purchasing an additional 108 shares in the last quarter. Finally, Fiera Capital Corp grew its position in shares of Krystal Biotech by 0.8% in the second quarter. Fiera Capital Corp now owns 16,208 shares of the company’s stock valued at $2,976,000 after purchasing an additional 130 shares in the last quarter. 86.29% of the stock is currently owned by hedge funds and other institutional investors.

Krystal Biotech Company Profile

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).